Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $225.33, for a total value of $32,672.85. Following the transaction, the senior vice president now directly owns 6,388 shares of the company’s stock, valued at approximately $1,439,408.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Charles Dadswell also recently made the following trade(s):
- On Friday, November 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The stock was sold at an average price of $207.88, for a total value of $334,478.92.
- On Tuesday, October 3rd, Charles Dadswell sold 145 shares of Illumina stock. The stock was sold at an average price of $202.23, for a total value of $29,323.35.
Shares of Illumina, Inc. (ILMN) traded up $2.92 during trading on Wednesday, hitting $213.98. The stock had a trading volume of 654,770 shares, compared to its average volume of 957,041. Illumina, Inc. has a one year low of $119.37 and a one year high of $230.72. The company has a market cap of $30,920.00, a PE ratio of 62.41, a P/E/G ratio of 3.53 and a beta of 0.79. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same quarter in the prior year, the business posted $0.97 EPS. The business’s revenue was up 17.6% compared to the same quarter last year. analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in ILMN. Dupont Capital Management Corp bought a new stake in Illumina in the 3rd quarter valued at $153,000. Advisory Services Network LLC raised its stake in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Penserra Capital Management LLC raised its stake in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares during the period. Paradigm Asset Management Co. LLC raised its stake in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares during the period. Finally, West Coast Financial LLC bought a new stake in Illumina in the 3rd quarter valued at $216,000. Institutional investors own 91.75% of the company’s stock.
A number of equities analysts have weighed in on ILMN shares. Citigroup upped their price target on Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 25th. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $184.00 to $228.00 in a research report on Wednesday, October 25th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target for the company in a research report on Friday, October 27th. Barclays upped their price target on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Finally, BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $201.98.
WARNING: This piece was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://ledgergazette.com/2017/12/06/insider-selling-illumina-inc-ilmn-svp-sells-145-shares-of-stock.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.